Update on guidelines for the treatment of chronic musculoskeletal pain

Clinical Rheumatology

Volumn 25, Issue SUPPL. 7, 2006, Pages

  Schnitzer, Thomas J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Combination therapy; Pain management; Paracetamol; Treatment guidelines; Weak opioid; Working Group on Pain Management

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CAPSAICIN; CELECOXIB; CHONDROITIN SULFATE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GLUCOSAMINE; IBUPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PARECOXIB; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; TRAMADOL; VALDECOXIB;

AGING; ANGINA PECTORIS; BLEEDING DISORDER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CHRONIC PAIN; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EUROPEAN UNION; GASTROINTESTINAL SYMPTOM; HEALTH CARE ORGANIZATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; JOINT SURGERY; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LONG TERM CARE; LOW BACK PAIN; LUNG EDEMA; MUSCULOSKELETAL PAIN; NEUROPATHIC PAIN; NEUROTOXICITY; OSTEOARTHRITIS; OTOTOXICITY; PATIENT CARE; PHYSIOTHERAPY; POPULATION RESEARCH; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PUBLISHING; REVIEW; RHEUMATOLOGY; SKIN DISEASE; STROKE; THROMBOSIS; TREATMENT PLANNING; ULCER; UNITED STATES;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; MUSCULOSKELETAL SYSTEM; PAIN; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; TRAMADOL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33745315683     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0203-8     Document Type: Review

References (36)

1. Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA (1999) The epidemiology of chronic pain in the community. Lancet 354:1248-1252
2. March LM, Bagga H (2004) Epidemiology of osteoarthritis in Australia. Med J Aust 180(5 Suppl):S6-S10
3. Blower AL, Brooks A, Fenn GC et al (1997) Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 11:283-291
4. Boureau F, Legallicier P, Kabir-Ahmadi M (2003) Tramadol in post-herpetic neuralgia: A randomized, double-blind, placebo-controlled trial. Pain 104:323-331
5. van Tulder MW, Scholten RJ, Koes BW, Deyo RA (2000) Nonsteroidal anti-inflammatory drugs for low back pain: A systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine 25:2501-2513
6. van Tulder MW, Scholten RJ, Koes BW, Deyo RA (2000) Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev (2):CD000396
7. Koes BW, Scholten RJ, Mens JM, Bouter LM (1997) Efficacy of non-steroidal anti-inflammatory drugs for low back pain: A systematic review of randomised clinical trials. Ann Rheum Dis 56:214-223
8. Singh G, Triadafilopoulos G (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 26(Suppl 56):18-24
9. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ (2000) Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 85:169-182
10. Emery P, Zeidler H, Kvien TK et al (1999) Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 354:2106-2111
11. Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ (1999) Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial. Clin Ther 21:1653-1663
12. Laine L, Harper S, Simon T et al (1999) A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117:776-783
13. Schnitzer TJ, Truitt K, Fleischmann R et al (1999) The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 21:1688-1702
14. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines (2000) Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43:1905-1915
15. Simon LS, Lipman AG, Jacox AK et al (2002) Pain in osteoarthritis, rheumatoid arthritis and juvenile chronic arthritis. In: Clinic practice guideline, no. 2. American Pain Society (APS), Glenview, IL, pp 179
16. Jordan KM, Arden NK, Doherty M et al (2003) EULAR recommendations 2003: an evidence-based approach to the management of knee osteoarthritis [Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)]. Ann Rheum Dis 62:1145-1155
17. Bombardier C, Laine L, Reicin A, VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520-1528
18. Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102
19. Merck press release. Merck announces voluntary worldwide withdrawal of Vioxx. http://www.vioxx.com/rofecoxib/vioxx/consumer/ press_release_09302004.jsp. Accessed November 2005
20. Solomon SD, McMurray JJ, Pfeffer MA, Adenoma Prevention with Celecoxib (APC) Study Investigators et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080
21. Ott E, Nussmeier NA, Duke PC, Multicenter Study of Perioperative Ischemia (McSPI) Research Group, Ischemia Research and Education Foundation (IREF) Investigators et al (2003) Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125:1481-1492
22. Nussmeier NA, Whelton AA, Brown MT et al (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081-1091
23. Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ 330:1366
24. Sudbo J, Lee JJ, Lippman SM et al (2005) Non-steroidal anti-inflammatory drugs and the risk of oral cancer: A nested case-control study. Lancet 366(9494):1359-1366
25. FDA talk paper. FDA issues public health advisory recommending limited use of COX-2 inhibitors. December 2004. Downloaded November 2005. http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01336.html
26. EMEA press statement, 17 February 2005 European Medicines Agency announces regulatory action on COX-2 inhibitors. http://www.emea.eu.int/ pdfs/human/press/pr/6275705en.pdf. Accessed November 2005
27. FDA memorandum, April 6, 2005. Downloaded November 2005. http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf
28. FDA public health advisory. FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). April 7, 2005. Downloaded November 2005. http://www.fda.gov/cder/drug/advisory/COX2.htm
29. EMEA press release, 27 June 2005. European Medicines Agency concludes action on COX-2 inhibitors. http://www.emea.eu.int/pdfs/human/press/pr/ 20776605en.pdf. Accessed November 2005
30. EMEA press statement, 7 April 2005. European Medicines Agency statement on the suspension of use of Bextra. http://www.emea.eu.int/htms/hotpress/ h12163705.htm. Accessed November 2005
31. EMEA press release, 2 August 2005. Accessed November 2005
32. EMEA press release, 17 October 2005. European Medicines Agency update on non-selective NSAIDs. http://www.emea.eu.int/pdfs/human/press/pr/ 29896405en.pdf. Accessed November 2005
33. Towheed TE, Maxwell L, Anastassiades TP et al (2005) Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev (2):CD002946
34. Uebelhart D, Malaise M, Marcolongo R et al (2004) Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: A one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthr Cartil 12:269-276
35. Moore N, Charlesworth A, Van Ganse E et al (2003) Risk factors for adverse events in analgesic drug users: Results from the PAIN study. Pharmacoepidemiol Drug Saf 12:601-610
36. Selvin E, Erlinger TP (2004) Prevalence of and risk factors for peripheral arterial disease in the United States. Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110:738-743